Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of all issues and individual articles published by the Journal since 1997.

Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure

Author(s):  Ma Nathan, Perks William, Law Shirley, Iazzetta John, Walker Scott

Issue:  Nov/Dec 2020 - Volume 24, Number 6
View All Articles in Issue

Page(s):  519-527

Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 1
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 2
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 3
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 4
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 5
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 6
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 7
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 8
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 9

Download in electronic PDF format for $75

Abstract:  Finasteride is not commercially available in a liquid format, which stimulated the development of a stable and simple finasteride suspension formulation. The objectives of this work were to develop and test a finasteride suspension for 1) simplicity to compound, 2) pharmaceutical acceptability, 3) stability, and 4) potential for occupational exposure. The stability of commercial 5-mg finasteride tablets (50 mg/150 mL) was evaluated in water, Oral Mix, and OralMix SF in amber polyethylene terephthalate bottles at 25°C or 4°C. Additional stability studies were carried out using sugar-free Finasteride Powder USP in amber polyethylene terephthalate bottles and tablets in water in polypropylene oral syringes. On study days 0, 1, 3, 7, 14, 28, 38, 49, 63, and 90, the finasteride concentration was determined using a validated stability-indicating liquid chromatographic method. The potential occupational airborne exposure was evaluated by attempting to measure finasteride in 1000 liters of room air following shaking and nebulization. Finasteride suspension/dispersion formulations were prepared in water, Oral Mix, and Oral Mix SF from tablets and pure powder. All formulations retained more than 94.3% of the initial finasteride concentration, with 95% confidence, when stored for up to 90 days at room temperature or 4°C. Simulations of occupational exposure failed to demonstrate the presence of finasteride in room air following attempts to nebulize finasteride mixtures. We conclude that 333-µg/mL suspension/dispersions of finasteride in water or Oral Mix products will have more than 94.3% of the initial finasteride concentration remaining after 90 days, regardless of the formulation, container, or storage temperature. Although we could not detect finasteride in room air, given the analytical limits of the study, we estimate that exposure would unlikely exceed 3.6-µg/1000 liters of room air. Nevertheless, since current regulations are based on “no safe limit,” use of primary engineering controls and personal protective equipment as appropriate is recommended.

Related Keywords: finasteride, oral suspension, hazardous drug, occupational exposure, workplace safety, stability, vaporization, aerosolization, dispersion, nebulization

Related Categories: ENVIRONMENTAL , STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, PROFESSIONAL ISSUES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure
Ma Nathan
, Perks William, Law Shirley, Iazzetta John, Walker Scott
Nov/Dec 2020
Pg. 519-527

Safety Standards in Pharmaceutical Compounding, Part 1: The Occupational Safety and Health Administration
Greeson Nicole MH
, Mixon William, Allan W Chris
Jul/Aug 2020
Pg. 270-276

PreScription: Permissible Exposure Limits and United States Pharmacopeia Chapter <800>
Allen Loyd V Jr
Sep/Oct 2021
Pg. 356

How to Develop and Maintain a Hazardous Drug List
Dillon L Rad
May/Jun 2019
Pg. 182-186

Complying with Occupational Safety and Health Administration Regulations: A Guide for Compounding Pharmacists
Mixon Bill
, Nain John
May/Jun 2013
Pg. 182-190

Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety
Allen W Chris
, Greeson Nicole MH, Mixon William
Nov/Dec 2020
Pg. 451-458

Basics of Compounding for Hazardous Drugs, Part 2: Regulation and Sources of Contamination
Allen Loyd V Jr
Nov/Dec 2006
Pg. 446-448

Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding
Soefje Scott
, Rickabaugh Keith, Rajkumar Rahul, Wall Kathryn P
Nov/Dec 2021
Pg. 515-522

Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding (Reprint)
Soefje Scott
, Rickabaugh Keith, Rajkumar Rahul, Wall Kathryn P
Jan/Feb 2022
Pg. 72-79

Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Dillon L R
Jan/Feb 2020
Pg. 30-36

Basics of Compounding for Hazardous Drugs, Part 4: Developing the Hazardous Drugs List and Containment Workstations
Allen Loyd V Jr
Mar/Apr 2007
Pg. 149-151

Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets
Kaila Nitin
, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
May/Jun 2003
Pg. 233-239

Compounding Using Hazardous Drugs
Lau Kellie
Jul/Aug 2000
Pg. 261-263

Evaluation of Containment Ventilated Enclosure Performance in Absence of Negative Pressure Containment Secondary Engineering Control
Hutson Chad
, Day A J
Nov/Dec 2019
Pg. 511-518

Minimizing the Risk of Teratogenic Substance Exposure for Pregnant Compounding Pharmacists
Paoletti James E
, Benavides Tomas J
Nov/Dec 1998
Pg. 414-415

Hazardous Drug Enteral Device: A Closed System Device for Crushing and Dispersing Hazardous Drug Tablets for Enteral Administration
Lopez C Vidal
, Rios GL Quito
Sep/Oct 2022
Pg. 358-362

Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 11: Hazardous Drugs
Allen Loyd V Jr
, Okeke Claudia C
Jan/Feb 2009
Pg. 56-62

Prophylaxis Against Exposure to Bloodborne Pathogens During Compounding
Williams Angie
, Mixon William
Jan/Feb 2010
Pg. 14-18

Antineoplastic Drug Contamination on the Outside of Prepared Infusion Bags
Breukels Oscar
, van der Gronde Toon, Simons-Sanders Kathleen, Crul Mirjam
Jul/Aug 2018
Pg. 345-349

Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance
Greeson Nicole MH
, Mixon William, Allan W Chris
Sep/Oct 2020
Pg. 371-379

Return to Top